For years, the KRAS oncogene was considered a key cancer driver but impossible to target with drugs. Through resilient investigation, scientists recently developed effective therapies against it, proving that even long-held beliefs about 'undruggable' targets can be overturned with persistence.

Unlike earlier G12C-specific "RAS-off" drugs that lock KRAS in an inactive state, new "RAS-on" inhibitors form a tri-complex with an active form of RAS and an endogenous protein. This novel mechanism enables targeting of a much broader spectrum of RAS mutations, representing a significant breakthrough for treating pancreatic cancer.

A new class of KRAS inhibitors targets the active 'on-state' of the protein, a departure from earlier drugs that targeted the inactive 'off-state'. These 'tri-complex inhibitors' use a chaperone protein to bind to the active GTP-bound KRAS, preventing downstream signaling and creating a new therapeutic avenue.

A new class of drugs, "RAS on" inhibitors (e.g., daxorarasib), targets the active, GTP-bound state of KRAS. This mechanism is distinct from first-generation "RAS off" inhibitors (e.g., sotorasib) and is designed to treat patients who develop resistance, offering a subsequent line of targeted therapy.

Instead of directly blocking the mutated KRAS protein, daraxin racid acts as a 'molecular glue.' It binds to a separate chaperone protein, and this new complex then disables the mutated KRAS protein. This indirect, novel mechanism of action is a breakthrough for targeting a protein that has been notoriously difficult to drug.

Faced with the 'undruggable' switch two pocket in KRAS, Blossom Hill modifies the drug's properties rather than the protein target. By engineering a molecule with 'pseudo irreversible' characteristics, they create a long-lasting effect that compensates for the challenging binding pocket, thereby enhancing in-vivo efficacy.

There is emerging evidence for sequencing KRAS inhibitors based on their mechanism. The "on-state" inhibitor Eliron-RASIB has shown a 50% response rate in patients previously treated with "off-state" inhibitors like adagrasib, suggesting that the resistance mechanism determines the effectiveness of subsequent therapy.

The efficacy of new KRAS inhibitors is set to fundamentally shift pancreatic cancer research. These agents are expected to become the new standard therapeutic backbone, meaning future clinical trials will likely test new drugs in combination with a RAS inhibitor, moving beyond chemotherapy-only combinations.

To combat resistance to drugs like Osimertinib, Blossom Hill designed a molecule potent against the C797S resistance mutation and equally potent against original mutations. This dual efficacy, preventing cancer evolution, is central to their promising clinical results and is a key design principle for durable cancer therapies.